CA72-4(Cancerantigen72-4)wasoriginallydescribedasanantigenicdeterminantrecognizedbyB72.3,amurinemonoclonalantibodyraisedagainstamembraneextractofmammacarcinomametastases.CA72-4wasidentifiedasa1MDamucine-likeGlycoproteincomplextermedTAG-72(tumorassociatedantigen72).ThemolecularweightoftheTAG-72proteinis48kDa.ElevatedCA72-4levelsinserumandplasmahavebeenreportedinvariousmalignantdiseasesincludingcarcinomasofpancreas,stomach,gall,colon,mamma,ovaries,cervixandendometrium.Thehighestdiagnosticsensitivitiesarefoundforcarcinomasofthegastrointestinaltractandovaries.AlthoughsomebenigndiseasessuchasrheumaticdiseasesorovarycystsmayalsoresultinelevatedlevelsofCA72-4,clinicalstudiesdemonstrateddiagnosticspecificitiesofmorethan95%forgastrointestinalandovarianmalignancies.ThereisagoodcorrelationbetweenCA72-4levelsandtumorstageandsize.CA72-4istheMarkerofchoiceforthetherapeuticmonitoringandfollow-upcareofgastrointestinalcancerpatients.SuitablesecondmarkersareCA19-9orCEA.Additionally,CA72-4hasbeenusedasanindependentmarkerforthetherapeuticmonitoringandfollow-upcareofovariancancerpatients,inparticularinCA125negativepatients.

ThisproductrepresentstherightalternativetothesoondiscontinuedCA72-4RIAfromDiaSorin.Pleasecontactusifyoushouldneedanykitfortrialpurposes!Orifyoushouldneedanysupportregardingcomparisonstudies.Wewillbehappytoprovideyouwithexpectedhelp.